Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.33 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.31 |
| ▸ | MAPT | P10636 | 4/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6157594 | 0.77 | ALDH1A1 (0.38) | KMT2AMEN1ALDH1A1MAPTGRM5 | |
| SCHEMBL6851890 | 0.77 | NPC1 (0.53) | KMT2AMEN1ALDH1A1MAPTNPC1 | |
| SCHEMBL6852232 | 0.77 | ALDH1A1 (0.50) | KMT2AMEN1ALDH1A1MAPTGRM5 | |
| SCHEMBL4277785 | 0.75 | MELK (0.50) | KMT2AMEN1GAAHPGDPKM | |
| SCHEMBL6854298 | 0.75 | ERN1 (0.35) | KMT2AMEN1ADRA2AADRA2CGAA | |
| SCHEMBL29305012 | 0.75 | ALDH1A1 (0.37) | KMT2AMEN1GAAGLAHPGD | |
| SCHEMBL738274 | 0.74 | HDAC8 (0.41) | KMT2AMEN1ADRA2AADRA2CGAA | |
| SCHEMBL622637 | 0.74 | CDK5 (0.47) | GAAGLAALDH1A1CCNB2CDK1 | |
| SCHEMBL97819 | 0.74 | KMT2A (0.38) | KMT2AMEN1ADRA2AADRA2CGAA | |
| Methane SCHEMBL28258537 | 0.72 | CDK5 (0.46) | GAAGLAALDH1A1CCNB2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501519-A1 | 9-OXIME MACROLIDE ANTIBACTERIALS | Abbott Laboratories (US) | 2005-02-02 | — | — | EP | claimed |
| US-20040014691-A1 | 9-Oxime macrolide antibacterials | ABBOTT LABORATORIES | 2004-01-22 | — | — | US | claimed |
| WO-2003090761-A1 | 9-OXIME MACROLIDE ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2003-11-06 | — | — | WO | claimed |
| CN-1585775-A | 6-O-acyl ketolide derivatives of erythromycine useful as antibacterials | ORTHO MCNEIL PHARM INC (US) | 2005-02-23 | — | — | CN | disclosed |
| EP-1501519-A1 | 9-OXIME MACROLIDE ANTIBACTERIALS | Abbott Laboratories (US) | 2005-02-02 | — | — | EP | disclosed |
| US-6825170-B2 | ERYTHROMYCIN TYPE MACROLIDE WITH A FUSED OXAZOLONE RING | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-11-30 | — | — | US | disclosed |
| EP-1453847-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040014691-A1 | 9-Oxime macrolide antibacterials | ABBOTT LABORATORIES | 2004-01-22 | — | — | US | disclosed |
| WO-2003090761-A1 | 9-OXIME MACROLIDE ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003050132-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014691-A1 | 9-Oxime macrolide antibacterials | CYP2C9, CYP1B1, SULT1E1 | KMT2A 4107/4885MEN1 2234/4885ADRA2A 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.